TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study
Compared with targeted-immunotherapy group, patients with BCLC stage C HCC treated with TACE-HAIC combined with donafenib and ICIs demonstrated superior efficacy and acceptable safety.
Authors
- Linan Yin (ORCID: https://orcid.org/0009-0008-7402-9224)
- Wencheng Shao (ORCID: https://orcid.org/0000-0002-9109-5361)
- Xunbo Hou
- Ruibao Liu
- Wenhao Li (ORCID: https://orcid.org/0000-0001-5209-8933)
- Bowen Liu (ORCID: https://orcid.org/0000-0002-4194-8119)
- Xuesong Liu (ORCID: https://orcid.org/0000-0002-7736-0077)
- Peng Huang (ORCID: https://orcid.org/0000-0001-6501-9552)
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1669856
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09